Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shimada A, et al. Among authors: tsukimoto i. Blood. 2006 Mar 1;107(5):1806-9. doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15. Blood. 2006. PMID: 16291592 Free article.
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Tomizawa D, et al. Among authors: tsukimoto i. Pediatr Blood Cancer. 2007 Aug;49(2):127-32. doi: 10.1002/pbc.20944. Pediatr Blood Cancer. 2007. PMID: 16807916 Clinical Trial.
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, Tabuchi K, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Sano H, et al. Among authors: tsukimoto i. Int J Hematol. 2012 May;95(5):509-15. doi: 10.1007/s12185-012-1033-x. Epub 2012 Mar 10. Int J Hematol. 2012. PMID: 22407852
High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, Tsuchida M, Horibe K, Tsukimoto I, Adachi S, Kojima S, Hayashi Y. Shimada A, et al. Among authors: tsukimoto i. Int J Hematol. 2012 Oct;96(4):469-76. doi: 10.1007/s12185-012-1163-1. Epub 2012 Aug 23. Int J Hematol. 2012. PMID: 22915059
NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia.
Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, Kobayashi T, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shiba N, et al. Among authors: tsukimoto i. Genes Chromosomes Cancer. 2013 Jul;52(7):683-93. doi: 10.1002/gcc.22064. Epub 2013 Apr 30. Genes Chromosomes Cancer. 2013. PMID: 23630019
WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group.
Sano H, Shimada A, Tabuchi K, Taki T, Murata C, Park MJ, Ohki K, Sotomatsu M, Adachi S, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Sano H, et al. Among authors: tsukimoto i. Int J Hematol. 2013 Oct;98(4):437-45. doi: 10.1007/s12185-013-1409-6. Epub 2013 Aug 27. Int J Hematol. 2013. PMID: 23979985
Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children.
Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, Kaneko T, Takano T, Ikuta K, Tsukimoto I; Japan Childhood Aplastic Anemia Study Group. Kojima S, et al. Among authors: tsukimoto i. Blood. 2002 Aug 1;100(3):786-90. doi: 10.1182/blood.v100.3.786. Blood. 2002. PMID: 12130487 Free article. Clinical Trial.
Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I; Japanese Childhood AML Cooperative Study Group. Kudo K, et al. Among authors: tsukimoto i. J Clin Oncol. 2007 Dec 1;25(34):5442-7. doi: 10.1200/JCO.2007.12.3687. J Clin Oncol. 2007. PMID: 18048827 Clinical Trial.
105 results